Generating CAM aspect-oriented architectures using Model-Driven Development |
| |
| Affiliation: | 1. The College of Biotechnology and Pharmaceutical Engineering, Nanjing University of Technology, No. 30 Puzhu Road, Nanjing 211800, PR China;2. Jiangsu Simcere Pharmaceutical Co. Ltd, Jiangsu Key Laboratory of Molecular Targeted Antitumor Drug Research, No. 699-18, Xuan Wu District, Nanjing 210042, PR China;3. Department of Medicinal Chemistry, School of Pharmacy, Health Science Center, Xi’an Jiaotong University, No. 76, Yanta West Road, Xi’an 710061, PR China;1. Department of Chemistry, Federal University of Sergipe, São Cristóvão, Sergipe, Brazil;2. Gonçalo Moniz Research Center, Oswaldo Cruz Foundation (Fiocruz), Rua Waldemar Falcão, 121, Candeal, 40296-710 Salvador, Bahia, Brazil;3. NMR Center, Department of Chemistry, Federal University of Paraná, Curitiba, Paraná, Brazil;4. Center of Biotechnology and Cell Therapy, Hospital São Rafael, Salvador, Bahia, Brazil;5. Department of Chemistry, Federal University of Sergipe, Itabaiana, Sergipe, Brazil;1. Laboratory of Medicinal and Advanced Synthetic Chemistry (Lab MASC), Department of Pharmaceutical Sciences, University of Perugia, Via del Liceo 1, Perugia I-06123, Italy;2. Laboratory of Bioinorganic Chemistry, University of Florence, Via della Lastruccia 3, Sesto Fiorentino (Firenze) I-50019, Italy;3. Neurofarba Dept., Section of Pharmaceutical and Nutriceutical Sciences, University of Florence, Via U. Schiff 6, Sesto Fiorentino (Firenze) I-50019, Italy;1. Département de Chimie, Université de Montréal, C.P. 6128 Succursale Centre-Ville, Montréal H3C 3J7 QC, Canada;2. Département de Pharmacologie, Université de Montréal, C.P. 6128 Succursale Centre-Ville, Montréal H3C 3J7 QC, Canada;1. Department of Medicinal Chemistry, Amgen Inc., 360 Binney St., Cambridge, MA 02142, USA;2. Department of Pharmaceutics, Amgen Inc., 360 Binney St., Cambridge, MA 02142, USA;3. Department of Neuroscience, Amgen Inc., 360 Binney St., Cambridge, MA 02142, USA;4. Department of Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA;5. Department of Pharmacokinetics & Drug Metabolism, Amgen Inc., 360 Binney St., Cambridge, MA 02142, USA;1. Graduate School of Pharmaceutical Sciences, Osaka University, Yamada-oka 1-6, Suita, Osaka 565-0871, Japan;2. Department of Molecular-Targeting Cancer Prevention, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan |
| |
| Abstract: | Aspect-Oriented Software Development promotes the separation of those concerns that cut across several components and/or are tangled with the base functionality of a component, through all phases of the software lifecycle. The benefit of identifying these crosscutting concerns (aspects) at the architectural level in particular is to improve the architecture design and its subsequent evolution, before moving onto detailed design and implementation. However, software architects are not usually experts on using specific AO architecture notations. Therefore, the aim of this paper is to provide support to define and specify aspect-oriented (AO) architectures using non-AO ones as the source. We will use the Model-Driven Development approach to transform a component-based architecture model into an AO architecture model. The CAM (component and aspect model) model and the DAOP–ADL language are the proposals used for modelling and specifying AO architectures. We will show how we automated part of the process and the tool support. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
